Dignitana AB (publ) (DIGN.ST)
SEK 0.92
(-2.65%)
SEK 0.92
(-2.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -264 Thousand SEK | 69.69% |
| 2022 | -6.6 Million SEK | 77.08% |
| 2021 | -28.81 Million SEK | -6.85% |
| 2020 | -30.23 Million SEK | -1.16% |
| 2019 | -31.58 Million SEK | -60.99% |
| 2018 | -16.55 Million SEK | 52.74% |
| 2017 | -35.13 Million SEK | -23.72% |
| 2016 | -28.31 Million SEK | -78.11% |
| 2015 | -15.91 Million SEK | -49.44% |
| 2014 | -11.01 Million SEK | 34.81% |
| 2013 | -16.71 Million SEK | -29.46% |
| 2012 | -12.7 Million SEK | -285.83% |
| 2011 | -3.16 Million SEK | 66.72% |
| 2010 | -9.81 Million SEK | -4.3% |
| 2009 | -9.41 Million SEK | -61.01% |
| 2008 | -5.84 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -6.97 Million SEK | -1134.2% |
| 2024 Q1 | -10.05 Million SEK | -246.22% |
| 2023 Q3 | 968 Thousand SEK | 386.39% |
| 2023 FY | - SEK | 69.69% |
| 2023 Q4 | -218 Thousand SEK | -122.52% |
| 2023 Q1 | 195 Thousand SEK | 102.55% |
| 2023 Q2 | -338 Thousand SEK | -273.33% |
| 2022 Q3 | 226 Thousand SEK | -93.72% |
| 2022 Q4 | -7.64 Million SEK | -3480.53% |
| 2022 FY | - SEK | 77.08% |
| 2022 Q1 | -2.78 Million SEK | 66.09% |
| 2022 Q2 | 3.59 Million SEK | 229.07% |
| 2021 Q1 | -3.77 Million SEK | 66.52% |
| 2021 Q3 | -10.4 Million SEK | -62.16% |
| 2021 Q4 | -8.21 Million SEK | 21.04% |
| 2021 FY | - SEK | -6.85% |
| 2021 Q2 | -6.41 Million SEK | -70.21% |
| 2020 FY | - SEK | -1.16% |
| 2020 Q1 | -8.71 Million SEK | 26.75% |
| 2020 Q3 | -5.17 Million SEK | -2.2% |
| 2020 Q4 | -11.26 Million SEK | -117.48% |
| 2020 Q2 | -5.06 Million SEK | 41.9% |
| 2019 Q2 | -5.16 Million SEK | -84.54% |
| 2019 Q1 | -2.79 Million SEK | 33.3% |
| 2019 Q3 | -6.78 Million SEK | -31.36% |
| 2019 Q4 | -11.9 Million SEK | -75.47% |
| 2019 FY | - SEK | -60.99% |
| 2018 Q3 | -3.45 Million SEK | -38.26% |
| 2018 Q1 | -6.43 Million SEK | 45.81% |
| 2018 Q2 | -2.49 Million SEK | 61.19% |
| 2018 Q4 | -4.19 Million SEK | -21.55% |
| 2018 FY | - SEK | 52.74% |
| 2017 FY | - SEK | -23.72% |
| 2017 Q4 | -11.87 Million SEK | -50.11% |
| 2017 Q3 | -7.9 Million SEK | 9.39% |
| 2017 Q2 | -8.72 Million SEK | -33.77% |
| 2017 Q1 | -6.52 Million SEK | 36.67% |
| 2016 Q4 | -10.3 Million SEK | -75.16% |
| 2016 Q3 | -5.88 Million SEK | 20.98% |
| 2016 FY | - SEK | -78.11% |
| 2016 Q1 | -5.45 Million SEK | -10.22% |
| 2016 Q2 | -7.44 Million SEK | -36.53% |
| 2015 Q4 | -4.94 Million SEK | -21.96% |
| 2015 FY | - SEK | -49.44% |
| 2015 Q3 | -4.05 Million SEK | 4.66% |
| 2015 Q2 | -4.25 Million SEK | -60.9% |
| 2015 Q1 | -2.64 Million SEK | -164.27% |
| 2014 Q2 | -2.4 Million SEK | 50.29% |
| 2014 Q1 | -4.83 Million SEK | -3.78% |
| 2014 FY | - SEK | 34.81% |
| 2014 Q4 | -1 Million SEK | 58.2% |
| 2014 Q3 | -2.39 Million SEK | 0.53% |
| 2013 Q2 | -4.42 Million SEK | -17.17% |
| 2013 Q1 | -3.77 Million SEK | 31.41% |
| 2013 Q3 | -3.45 Million SEK | 21.89% |
| 2013 Q4 | -4.66 Million SEK | -34.94% |
| 2013 FY | - SEK | -29.46% |
| 2012 FY | - SEK | -285.83% |
| 2012 Q1 | -1.38 Million SEK | 81.13% |
| 2012 Q3 | -2.88 Million SEK | 0.9% |
| 2012 Q4 | -5.5 Million SEK | -90.95% |
| 2012 Q2 | -2.9 Million SEK | -110.8% |
| 2011 Q1 | -3.07 Million SEK | 21.66% |
| 2011 Q2 | 6.14 Million SEK | 300.01% |
| 2011 FY | - SEK | 66.72% |
| 2011 Q4 | -7.31 Million SEK | -142.33% |
| 2011 Q3 | -3.01 Million SEK | -149.12% |
| 2010 Q1 | -1.81 Million SEK | 51.55% |
| 2010 Q2 | -2.8 Million SEK | -54.54% |
| 2010 Q4 | -3.92 Million SEK | -208.07% |
| 2010 Q3 | -1.27 Million SEK | 54.64% |
| 2010 FY | - SEK | -4.3% |
| 2009 Q4 | -3.74 Million SEK | -32.97% |
| 2009 Q2 | -2.04 Million SEK | -40.7% |
| 2009 FY | - SEK | -61.01% |
| 2009 Q1 | -1.45 Million SEK | 0.0% |
| 2009 Q3 | -2.81 Million SEK | -38.02% |
| 2008 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 99.658% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 100.064% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 100.064% |
| Arcoma AB | 6.24 Million SEK | 104.225% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 99.707% |
| BICO Group AB (publ) | 322.3 Million SEK | 100.082% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 100.4% |
| CellaVision AB (publ) | 207.24 Million SEK | 100.127% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 99.614% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 99.055% |
| C-Rad AB (publ) | 48.9 Million SEK | 100.54% |
| Duearity AB (publ) | -24.77 Million SEK | 98.935% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 99.699% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.004% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 99.607% |
| Iconovo AB (publ) | -35.33 Million SEK | 99.253% |
| Integrum AB (publ) | 8.76 Million SEK | 103.013% |
| Luxbright AB (publ) | -23.86 Million SEK | 98.894% |
| Mentice AB (publ) | 28.87 Million SEK | 100.914% |
| OssDsign AB (publ) | -122.02 Million SEK | 99.784% |
| Paxman AB (publ) | 31.22 Million SEK | 100.845% |
| Promimic AB (publ) | -3.68 Million SEK | 92.834% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 99.825% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 99.491% |
| ScandiDos AB (publ) | -13.35 Million SEK | 98.023% |
| Sectra AB (publ) | 615.06 Million SEK | 100.043% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 99.489% |
| Senzime AB (publ) | -118.82 Million SEK | 99.778% |
| SpectraCure AB (publ) | -20.96 Million SEK | 98.741% |
| Stille AB | 56.04 Million SEK | 100.471% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.992% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 100.209% |